The Case Western Reserve University Technology and Validation Start-Up Fund Program (CTP) recently announced the recipients of its second funding round of 2017.
CTP is awarded by the Ohio Third Frontier and managed through the CWRU Technology Transfer Office. The program aims to accelerate and fund the translation of promising technologies into the marketplace through Ohio-based companies with the eventual goal of creating greater economic growth. The $500,000 fund will help faculty researchers advance and commercialize their innovations. Three rounds of funding are expected in 2017.
The CTP is intended to be the final bridge between a translational research project and a viable commercial program. Funding will support technologies that require validation/proof that will directly impact and enhance commercial viability and the ability to support a start-up company.
The CTP will have one more funding round, with request for proposals to be announced in August 2017. Contact Stephanie Weidenbecher at saw43@case.edu for more information, or visit case.edu/research/faculty-staff/tto/technology-validation-and-start-up-fund/.
The three CTP award recipients for Round 2 are:
Dominique Durand, Department of Biomedical Engineering
Non-Invasive Sensory Stimulation for Seizure Suppression
The technology: A non-invasive, alternative method to prevent seizures using deep brain stimulation technology. A mask integrated with LEDs and earphones delivers low frequency stimulation through audio clicks and visual flashes to suppress seizures.
Anant Madabhushi, Department of Biomedical Engineering
Computerized Histologic Risk Predictor (CHiRP) of Benefit of Adjuvant Therapy in Lung Cancer
The technology: Software to predict disease recurrence in early stage lung cancer patients and help determine whether patients will benefit from adjuvant chemotherapy.
Miklos Gratzl, Department of Biomedical Engineering
Portable Sweat Chloride Tester For Early Diagnosis of Cystic Fibrosis
The technology: Fully automated, hand-held device to diagnose cystic fibrosis in newborns requiring only one-tenth of the sample size required by current technologies.